#JPM23: When will the IPO window open? What terms are startups getting? Here’s what to expect from capital markets this year

Executive Editor Drew Armstrong sat down with Bayer’s business development leader Marianne De Backer, PwC’s pharma deals chief Roel Van den Akker, and Sofinnova Investments General Partner Maha Katabi to talk about the IPO environment, trends in public and private fundraising, how negotiations between companies have changed and where capital...

Click to view original post